Stock Recommendations Today: Eicher Motors, HAL, Lupin, Jubilant FoodWorks On Brokerages' Radar

Eicher Motors Ltd., Hindustan Aeronautics Ltd., and Lupin Ltd. were among the top companies on brokerages' radar on Thursday.

According to Morgan Stanley, Eicher Motors missed Ebidta margin by 100 bps, but picking growth over margins is the right strategy.

In addition, Goldman Sachs sees Jubilant FoodWorks' growth momentum sustaining driven by LFL growth.

NDTV Profit tracks what analysts are saying about various stocks and sectors. Here are the analyst calls to keep an eye out for on Thursday.

Brokerages On Eicher Motors

Citi

• Citi maintained a 'buy' rating on Eicher Motors and raised the target price to Rs 6,200 from Rs 6,050.

• Fourth quarter Ebitda was slightly below estimates; however, higher other income supported profit.

• The demand outlook remains positive as management anticipates that tax cuts will boost urban demand in financial year 2026.

• Rural demand is already healthy.

• Volume growth may not translate into earnings if margins remain weak, according to Citi.

Morgan Stanley

• Morgan Stanley maintained an 'underweight' rating on Eicher Motors and raised the target price to Rs 4,079 from Rs 3,855.

• In the fourth quarter, the company focused on volume but missed margin expectations.

• Ebitda margin was 100 basis points below estimates for the second consecutive quarter.

• Prioritising growth over margins is considered the correct strategy.

• However, the stock is already pricing in high growth and high margins.

Brokerages On Jubilant Food

Citi

• Citi maintained a 'buy' rating on Jubilant FoodWorks and increased the target price to Rs 805 from Rs 750.

• The company is delivering gains in market share, growth, and profitability.

• Like-for-like sales continue to outperform other QSR players, suggesting potential for a re-rating.

• Jubilant remains Citi's preferred pick within its QSR coverage.

Goldman Sachs

• Goldman Sachs maintained a 'neutral' rating on Jubilant FoodWorks and increased the target price to Rs 730 from Rs 700.

• Fourth quarter was strong across all key metrics.

• Revenue growth momentum is sustained, driven by like-for-like growth.

• Ebitda margins have started to trend upwards as operating leverage begins to take effect.

Morgan Stanley On Sai Life

• Morgan Stanley maintained an 'overweight' rating on Sai Life and raised the target price to Rs 911 from Rs 865.

• A strong outlook has led to a sharp increase in capital expenditure.

• Sai's integrated CRDMO model is enabling it to outpace industry growth in both discovery and CDMO segments.

• The substantial capex increase reflects management's confidence in future growth.

JPMorgan On Hindustan Aeronautics

• JPMorgan maintains an 'overweight' rating on Hindustan Aeronautics with a target price of Rs 5,040.

• Fourth quarter results were ahead of expectations, supported by stronger Ebitda margins.

• Volatility in quarterly P&L is expected due to the nature of the business.

Investec On Biocon

• Investec initiates coverage on Biocon with a 'buy' rating and a target price of Rs 400.

• The company is well positioned, with successful execution now being key.

• Biocon is well-placed to leverage the global biosimilars opportunity.

• It is also benefiting from growth in both the generics (with GLP-1s being critical) and services businesses.

• The recent success in securing PBM formulary placements for Yesintek (bStelara) is a notable positive.

• Recent launches in the US and EU, along with upcoming approvals, are expected to drive growth and profitability.

• Planned restructuring, together with growth prospects, should support debt reduction.

Macquarie On Lupin

• Macquarie maintained an 'outperform' rating on Lupin with a target price of Rs 2,515.

• Fourth quarter of fiscal 2025 results showed a modest all-round beat.

• Research and development expenses increased sequentially, in line with management guidance.

Morgan Stanley On Muthoot Finance

• Morgan Stanley maintained an 'equal-weight' rating on Muthoot Finance with a target price of Rs 2,400.

• Despite higher costs, the company delivered a strong quarter.

• AUM and EPS grew by 43%, and ROE stood at 22%, driven by strong gold prices.

• Financial year 2026 is expected to be another year of robust earnings growth.

• The risk-reward profile is currently balanced.

• A decline in gold prices poses a risk to sentiment, while potential earnings downgrades across broader financials could offer upside.

Macquarie On Blue Jet Healthcare

• Macquarie maintained an 'outperform' rating on Blue Jet Healthcare with a target price of Rs 1,000.

• Fourth quarter results were a solid all-round beat, with an optimistic outlook for financial year 2026.

• The company is currently involved in 20 additional CDMO projects, with some nearing final development stages.

• Growth in the sweetener segment is expected to accelerate, driven by a new product launch in financial year 2026.

Nomura On Shree Cement

• Nomura maintained a 'buy' rating on Shree Cement with a target price of Rs 34,000.

• Strong realisations have led to the highest Ebitda per tonne.